203 related articles for article (PubMed ID: 35902282)
1. Engineering ACE2 decoy receptors to combat viral escapability.
Arimori T; Ikemura N; Okamoto T; Takagi J; Standley DM; Hoshino A
Trends Pharmacol Sci; 2022 Oct; 43(10):838-851. PubMed ID: 35902282
[TBL] [Abstract][Full Text] [Related]
2. High activity of an affinity-matured ACE2 decoy against Omicron SARS-CoV-2 and pre-emergent coronaviruses.
Sims JJ; Lian S; Meggersee RL; Kasimsetty A; Wilson JM
PLoS One; 2022; 17(8):e0271359. PubMed ID: 36006993
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.
Kuba K; Yamaguchi T; Penninger JM
Front Immunol; 2021; 12():732690. PubMed ID: 35003058
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants.
Ferrari M; Mekkaoui L; Ilca FT; Akbar Z; Bughda R; Lamb K; Ward K; Parekh F; Karattil R; Allen C; Wu P; Baldan V; Mattiuzzo G; Bentley EM; Takeuchi Y; Sillibourne J; Datta P; Kinna A; Pule M; Onuoha SC
J Virol; 2021 Sep; 95(19):e0068521. PubMed ID: 34287040
[TBL] [Abstract][Full Text] [Related]
5. Soluble ACE2 as a potential therapy for COVID-19.
Krishnamurthy S; Lockey RF; Kolliputi N
Am J Physiol Cell Physiol; 2021 Mar; 320(3):C279-C281. PubMed ID: 33502950
[TBL] [Abstract][Full Text] [Related]
6. A super-potent tetramerized ACE2 protein displays enhanced neutralization of SARS-CoV-2 virus infection.
Miller A; Leach A; Thomas J; McAndrew C; Bentley E; Mattiuzzo G; John L; Mirazimi A; Harris G; Gamage N; Carr S; Ali H; Van Montfort R; Rabbitts T
Sci Rep; 2021 May; 11(1):10617. PubMed ID: 34012108
[TBL] [Abstract][Full Text] [Related]
7. An albumin-angiotensin converting enzyme 2-based SARS-CoV-2 decoy with FcRn-driven half-life extension.
Fuchs E; Rudnik-Jansen I; Dinesen A; Selnihhin D; Mandrup OA; Thiam K; Kjems J; Pedersen FS; Howard KA
Acta Biomater; 2022 Nov; 153():411-418. PubMed ID: 36162760
[TBL] [Abstract][Full Text] [Related]
8. ACE2-based decoy receptors for SARS coronavirus 2.
Jing W; Procko E
Proteins; 2021 Sep; 89(9):1065-1078. PubMed ID: 33973262
[TBL] [Abstract][Full Text] [Related]
9. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
[TBL] [Abstract][Full Text] [Related]
10. Killing Two Birds with One Stone by Administration of Soluble ACE2: A Promising Strategy to Treat Both Cardiovascular Diseases and SARS-CoV-2 Infection.
Feng F; Chen J; Zhao J; Li Y; Li M; Sun C
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835049
[TBL] [Abstract][Full Text] [Related]
11. Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2.
Chan KK; Dorosky D; Sharma P; Abbasi SA; Dye JM; Kranz DM; Herbert AS; Procko E
Science; 2020 Sep; 369(6508):1261-1265. PubMed ID: 32753553
[TBL] [Abstract][Full Text] [Related]
12. Broadly Effective ACE2 Decoy Proteins Protect Mice from Lethal SARS-CoV-2 Infection.
Lu M; Yao W; Li Y; Ma D; Zhang Z; Wang H; Tang X; Wang Y; Li C; Cheng D; Lin H; Yin Y; Zhao J; Zhong G
Microbiol Spectr; 2023 Aug; 11(4):e0110023. PubMed ID: 37395664
[TBL] [Abstract][Full Text] [Related]
13. Generation of enzymatically competent SARS-CoV-2 decoy receptor ACE2-Fc in glycoengineered Nicotiana benthamiana.
Castilho A; Schwestka J; Kienzl NF; Vavra U; Grünwald-Gruber C; Izadi S; Hiremath C; Niederhöfer J; Laurent E; Monteil V; Mirazimi A; Wirnsberger G; Stadlmann J; Stöger E; Mach L; Strasser R
Biotechnol J; 2021 Jun; 16(6):e2000566. PubMed ID: 33481336
[TBL] [Abstract][Full Text] [Related]
14. A tetrameric ACE2 protein broadly neutralizes SARS-CoV-2 spike variants of concern with elevated potency.
Leach A; Ilca FT; Akbar Z; Ferrari M; Bentley EM; Mattiuzzo G; Onuoha S; Miller A; Ali H; Rabbitts TH
Antiviral Res; 2021 Oct; 194():105147. PubMed ID: 34375715
[TBL] [Abstract][Full Text] [Related]
15. Broad and Differential Animal Angiotensin-Converting Enzyme 2 Receptor Usage by SARS-CoV-2.
Zhao X; Chen D; Szabla R; Zheng M; Li G; Du P; Zheng S; Li X; Song C; Li R; Guo JT; Junop M; Zeng H; Lin H
J Virol; 2020 Aug; 94(18):. PubMed ID: 32661139
[TBL] [Abstract][Full Text] [Related]
16. ACE2 decoy receptor generated by high-throughput saturation mutagenesis efficiently neutralizes SARS-CoV-2 and its prevalent variants.
Wang B; Zhao J; Liu S; Feng J; Luo Y; He X; Wang Y; Ge F; Wang J; Ye B; Huang W; Bo X; Wang Y; Xi JJ
Emerg Microbes Infect; 2022 Dec; 11(1):1488-1499. PubMed ID: 35587428
[TBL] [Abstract][Full Text] [Related]
17. An inhaled ACE2 decoy confers protection against SARS-CoV-2 infection in preclinical models.
Urano E; Itoh Y; Suzuki T; Sasaki T; Kishikawa JI; Akamatsu K; Higuchi Y; Sakai Y; Okamura T; Mitoma S; Sugihara F; Takada A; Kimura M; Nakao S; Hirose M; Sasaki T; Koketsu R; Tsuji S; Yanagida S; Shioda T; Hara E; Matoba S; Matsuura Y; Kanda Y; Arase H; Okada M; Takagi J; Kato T; Hoshino A; Yasutomi Y; Saito A; Okamoto T
Sci Transl Med; 2023 Aug; 15(711):eadi2623. PubMed ID: 37647387
[TBL] [Abstract][Full Text] [Related]
18. A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19.
Malek Mahdavi A
Rev Med Virol; 2020 Sep; 30(5):e2119. PubMed ID: 32584474
[TBL] [Abstract][Full Text] [Related]
19. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
[TBL] [Abstract][Full Text] [Related]
20. David versus goliath: ACE2-Fc receptor traps as potential SARS-CoV-2 inhibitors.
Alfaleh MA; Zawawi A; Al-Amri SS; Hashem AM
MAbs; 2022; 14(1):2057832. PubMed ID: 35380919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
